Business Wire

TX-FLUENCE

9.6.2021 13:02:11 CEST | Business Wire | Press release

Share
Fluence Expands Footprint in Burgeoning Israeli Cannabis Industry, Supports Multiple Cultivators Through REMY Partnership

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis LTD and UNIVO Pharmaceuticals (UNIVO), through Fluence’s ongoing partnership with REMY LTD (REMY), a leading, Israel-based horticultural lighting provider to the country’s growing agriculture industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005120/en/

Following the legalization of medical cannabis in 1993, Israel’s cannabis industry has flourished through in-depth research into efficient production and cultivation processes. With nearly 30 cultivators actively producing medical cannabis and dozens in planning stages, Israel is poised to meet and exceed demand for the estimated 100,000 medical cannabis users throughout the country. As legislation to legalize recreational cannabis use is evaluated, experts predict the industry will maintain its exponential growth trajectory.

“The rapid growth of the medical cannabis industry in Israel is a clear indicator of the recreational market’s potential,” said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. “To maintain the industry’s pace, cultivators must examine and invest in highly efficient production methods that yield consistent, high-quality cannabis products. Lighting plays one of the most crucial roles in that production process.”

Optimal lighting strategies for every phase of the cultivation value chain

Whether seed and variety breeding, cloning and growing plants, or the final cultivation of dense and full buds, each phase of the cannabis value chain requires optimized, curated lighting conditions. Fluence not only offers the industry’s leading LED lighting solutions, but provides evidence-based best practices to identify, implement and maintain the optimal lighting strategy at each phase of cannabis growth. Fluence’s research-backed cultivation methods supported by its team of horticulture specialists enable cannabis cultivators to achieve high-quality, consistent crops while conserving heating, ventilation and air conditioning costs.

REMY echoes Fluence’s cultivation philosophy and approach. Through their partnership, Fluence and REMY are serving Israel’s most innovative cultivators. Springs Valley Cannabis, located in Northern Israel, relies on Fluence’s LED technology in its large-scale, high-end indoor growing facility to ensure superior cannabis flowering within the company’s first cultivation environment.

“Lighting has a major effect on our high-end indoor farm's success,” said Yair Shaked, CEO at Springs Valley Cannabis. “We searched for a lighting partner that would support us and add value for the long run—that's why we chose to work with REMY and Fluence.”

UNIVO, a vertically integrated medical cannabis company covering all aspects of cultivation, manufacturing and distribution, leverages Fluence’s solutions in different stages of the growth cycle, including nursery, vegetative, flowering, mother stock, and research and development, where UNIVO clones and grows cannabis plants.

“Amit farm by UNIVO is one of the most sophisticated and technological farms in the Israeli cannabis industry, and after carefully reviewing the market, we decided to cooperate with Fluence to achieve the best premium cannabis flowers,” added Golan Bitton, CEO at UNIVO.

Continuous investment in new knowledge

“Amid Israel’s revered, dynamic high-tech industry, Fluence’s LED lighting technology is recognized as truly innovative. To maintain that position, we continuously invest in new knowledge and develop new techniques to best serve the world’s cultivators,” Bongartz added.

Fluence works closely with leading research institutions such as Wageningen University & Research to uncover new cultivation strategies and explore the influence of various light spectra on cannabis growth and development. Fluence’s collaborative research insights inform product innovations and provide growers with effective best practices to optimize plant growth.

“The job doesn’t stop when the light fixtures have been installed,” says Jörg Meyer-Brenken, Fluence’s lead account manager for cannabis in EMEA. “On the contrary, that’s when it starts and that’s where the Fluence and REMY teams add extraordinary value. REMY is a true, reliable partner. Their team combines deep lighting knowledge with years of experience in Israeli agriculture and horticulture, making REMY an ideal partner to help us reach a prominent position in this fast-growing market.”

“The end result for the cultivator is an agronomic lighting fixture, but the path to reach the optimal lighting strategy is driven by years of research and practical knowledge,” said Elad Toby, founder, CTO and chief business development officer for REMY. “There is huge opportunity in bringing Fluence’s groundbreaking knowledge to the Israeli medical cannabis market.”

For more information about Fluence, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .

About REMY

Established in 2008, REMY 108 LTD specializes in the planning, installation, supervision and quality assurance of large-scale lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its showroom and headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye